Drug lookup
Drug reference

Mycophenolate Mofetil

Immunosuppressant · Immunosuppressant; Prophylaxis of graft rejection in renal transplantation

Also known as Myfenax, Mycophenolate mofetil hydrochloride

ImmunosuppressantImmunosuppressant; Prophylaxis of graft rejection in renal transplantation
CDSCO approvedSchedule H
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Avoid unless no suitable alternative; associated with congenital malformations and spontaneous abortions.
FDA category + note
Top interactionssee all 12
  • Activated CharcoalSevereDatabaseDDInter
  • AdalimumabSevereDatabaseDDInter
  • AmoxycillinSevereDatabase
  • BaricitinibSevereDatabaseDDInter

Mechanism

Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), a selective, reversible, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) type II — the rate-limiting enzyme in the de novo pathway of guanosine nucleotide synthesis. Because T and B lymphocytes depend almost exclusively on this de novo pathway (unlike most other cells that can use the salvage pathway), MPA selectively suppresses lymphocyte proliferation while relatively sparing other rapidly dividing cells. This immunological selectivity provides effective immunosuppression with less myelotoxicity than azathioprine.

Indications

Prophylaxis of organ rejection in adults undergoing kidney transplantationprophylaxis of transplant rejectionsystemic lupus erythematosus (off-label)ms (off-label)sarcoidosis (off-label)induction and maintenance of remission in difficult-to-treat IBDpatients who are intolerant of thiopurinessteroid-dependent patients

Dosing

Adult
doses should be reduced when allopurinol p. 1183 is given concurrently. Mycophenolate mofetil is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine.…

Contraindications

  • Pregnancy (unless no suitable alternative due to reported congenital malformations and spontaneous abortions)
  • pregnancy

Side effects

Common
dizzinessgouthepatic disordershyperbilirubinaemiahyperuricaemianeuromuscular dysfunctiontaste alteredvasodilationgi (diarrhea and vomiting)hematological (leukopenia, pure red cell aplasia) problemscolitis (paradoxical, reported in patients using it to prevent transplant rejection)
Serious
  • pure red cell aplasia
  • bone marrow suppression (e.g., infection, inexplicable bruising or bleeding)

Pregnancy & lactation

Pregnancy

Avoid unless no suitable alternative; associated with congenital malformations and spontaneous abortions.

Lactation

Manufacturer advises to avoid; present in milk in animal studies.

Drug interactions

Activated Charcoal
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Adalimumab
Severe
Database

Drug interaction classified as: synergy.

Source: DDInter

Amoxycillin
Severe
Database

Decreased plasma concentrations of mycophenolic acid, leading to reduced immunosuppressive effect and an increased risk of transplant rejection.

Monitor mycophenolic acid levels closely. Consider alternative antibiotic or increased mycophenolate dose. Monitor for signs of transplant rejection.

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Certolizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cholestyramine
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Cladribine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Colesevelam
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Colestipol
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Deferiprone
Severe
Database

Clinical effect not specified

Source: DDInter

Desogestrel
Severe
Database

Clinical effect not specified

Source: DDInter

Dienogest
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Other Immunosuppressant drugs

Ask House about Mycophenolate Mofetil

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team